Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Form 8.5 (EPT/RI)

11 Jul 2025 10:55

RNS Number : 7620Q
Panmure Liberum Limited
11 July 2025
Β 

FORM 8.5 (EPT/RI)

Β 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Panmure Liberum Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Life Science REIT plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Life Science REIT plc

(d) Date dealing undertaken:

10 Jul 2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchases/ sales

Β 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

1p ordinary

Purchase

22,596

0.438 GBP

0.436 GBP

Β 

(b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing, or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

3. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

Β 

Date of disclosure:

11/07/2025

Contact name:

Rosie Kinsella

Telephone number:

+44 (0)207 886 2574

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FERKZGMNLMFGKZG
Date   Source Headline
29th Jan 202612:19 pmRNSForm 8.3 - British Land Co PLC, The
29th Jan 202612:13 pmRNSForm 8.3 - Life Science REIT PLC
29th Jan 202611:58 amRNSForm 8.5 (EPT/RI)- Life Science REIT plc
29th Jan 202611:49 amRNSForm 8.3 Life Science REIT Plc
29th Jan 202611:39 amRNSForm 8.5 (EPT/RI)
29th Jan 202610:09 amRNSForm 8.5 (EPT/RI)-Life Science REIT plc
29th Jan 202610:06 amRNSForm 8.3
29th Jan 202610:02 amRNSForm 8.5 (EPT/NON-RI)-Life Science REIT plc
28th Jan 20262:54 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 20262:19 pmRNSForm 8.3 - Life Science REIT Plc
28th Jan 20261:55 pmRNSForm 8.3 - British Land Company plc, The
28th Jan 20261:52 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 202611:47 amRNSForm 8.3 - Life Science REIT plc
28th Jan 202610:22 amRNSForm 8.3 - Life Science REIT plc
28th Jan 20267:50 amRNSDisclosure Table
28th Jan 20267:00 amRNSRecommended offer for Life Science REIT PLC
27th Jan 20262:39 pmRNSHolding(s) in Company
26th Jan 20262:38 pmRNSHolding(s) in Company
26th Jan 202610:48 amRNSHolding(s) in Company
23rd Jan 20264:49 pmRNSHolding(s) in Company
23rd Jan 20262:58 pmRNSHolding(s) in Company
22nd Jan 20264:16 pmRNSHolding(s) in Company
22nd Jan 20263:16 pmRNSHolding(s) in Company
21st Jan 20262:56 pmRNSHolding(s) in Company
16th Jan 202612:17 pmRNSHolding(s) in Company
15th Jan 20263:43 pmRNSHolding(s) in Company
14th Jan 20264:59 pmRNSHolding(s) in Company
9th Jan 20267:00 amRNSPortfolio Valuation and NTA Update
22nd Dec 20253:01 pmRNSHolding(s) in Company
22nd Dec 20253:01 pmRNSHolding(s) in Company
16th Dec 20255:19 pmRNSHolding(s) in Company
3rd Dec 20257:00 amRNSAppointment of Non-Executive Director
1st Dec 202510:17 amRNSHolding(s) in Company
26th Nov 20254:34 pmRNSHolding(s) in Company
24th Nov 20253:58 pmRNSResult of Meeting
20th Nov 202510:12 amRNSHolding(s) in Company
19th Nov 202510:07 amRNSHolding(s) in Company
13th Nov 20253:02 pmRNSHolding(s) in Company
6th Nov 20255:19 pmRNSHolding(s) in Company
5th Nov 20259:43 amRNSHolding(s) in Company
4th Nov 20257:00 amRNSPublication of Circular & Notice of GM
20th Oct 20255:03 pmRNSHolding(s) in Company
20th Oct 20253:53 pmRNSHolding(s) in Company
17th Oct 20253:58 pmRNSHolding(s) in Company
16th Oct 20253:36 pmRNSHolding(s) in Company
10th Oct 20253:13 pmRNSForm 8.3 - Life Science REIT plc
3rd Oct 20255:59 pmRNSHolding(s) in Company
23rd Sep 20253:17 pmRNSForm 8.3 - Life Science REIT plc
23rd Sep 20257:00 amRNSHalf Year Results
22nd Sep 20253:22 pmRNSForm 8.3 - Life Science REIT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.